ESC Premium Access

The combination of dulaglutide and dapagliflozin improves arterial stiffness, endothelial glycocalyx and albuminuria vs dpp4 inhibitors independently of glycemic control

Congress Presentation

About the speaker

Doctor Ignatios Ikonomidis

National & Kapodistrian University of Athens, Athens (Greece)
5 presentations
3 followers

224 more presentations in this session

High risk characteristics in patients with hypertrophic cardiomiyopathy for predicting cardiovascular events

Speaker: Doctor B. Keskin (Istanbul, TR)

Thumbnail

Cardiac biomarkers as prognosticators among SARS-CoV-19 patients in a tertiary hospital in Philippines

Speaker: Doctor R. Ong (Makati, PH)

Thumbnail

Prevalence of atherosclerosis risk factors in Egyptian patients with acute coronary syndromes; final data of the nationwide cross-sectional CardioRisk project

Speaker: Doctor A. Bendary (Benha, EG)

Thumbnail

SF-12 Physical and Mental Health Scales predict cardiovascular events after hospitalization

Speaker: Mr R. Gascuena (Leganes, ES)

Thumbnail

Comparison of traditional versus artificial intelligence based coronary artery disease risk prediction scores in young patients with acute coronary syndrome

Speaker: Doctor S. Vohra (Lucknow, IN)

Thumbnail

Access the full session

Risk Factors and Prevention ePosters

Speakers: Doctor I. Ikonomidis, Doctor B. Keskin, Doctor R. Ong, Doctor A. Bendary, Mr R. Gascuena...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

The ADDition of DAPAgliflozin to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory HFrEF

27 August 2021

ESC Premium Access

Influence of cardiovascular drugs on the efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial

27 August 2021

ESC Premium Access

The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failure

27 August 2021

ESC 365 is supported by

logo Novo Nordisk